Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
NCT07506876Phase 2Recruiting
- Sponsor
- Legacy Health
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by Legacy Health. Primary endpoint: Pathological Complete Response Rates at 21 months. Started Apr 2026; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07506876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07506876.